IONETIX is a pioneering radiopharmaceutical end-to-end solution provider.
Founded in 2009 from technology born at MIT Plasma Science and Fusion Center, IONETIX developed the world’s first commercial compact superconducting cyclotron, the ION-12SC used to produce N-13 Ammonia, one of the most accurate PET imaging agents for the detection of CAD.1
IONETIX is actively establishing a network of ION-12SCs installed on or near the campus of PET programs across the country. By covering all costs related to the installation and ongoing operation of the cyclotron and making N-13 Ammonia available to providers through a pay-by-the-dose model, we are making this critical tracer accessible and affordable to providers nationwide.
More recently, IONETIX is leveraging its growing network of radiopharmaceutical manufacturing locations to support the development and commercialization of targeted alpha therapy (TAT). An emerging cancer therapy utilizing alpha radionuclides, TAT delivers high-energy alpha particles to cancer cells and the tumor microenvironment to treat cancer while preserving healthy tissue.
OUR QUALITY POLICY